View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsARCA biopharma 과거 순이익 실적과거 기준 점검 0/6ARCA biopharma의 수입은 연평균 -2.1%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 36.2% 증가했습니다.핵심 정보-2.10%순이익 성장률51.90%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률-22.10%순이익률n/a최근 순이익 업데이트30 Jun 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates분석 기사 • Apr 04Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Apr 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 8.4% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$47.1m market cap).공시 • Feb 09Arca Biopharma, Inc. Announces Executive ChangesARCA biopharma, Inc. announced on February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors of the company, effective immediately. Upon the effectiveness of their resignations, Dr. Woosley and Mr. Mitchell each ceased to serve on any Board committees, including as Chairperson of the Nominating & Corporate Governance Committee and as member of the Compensation Committee, and as member of the Audit Committee and Nominating & Corporate Governance Committee, respectively. Each of Dr. Woosley’s and Mr. Mitchell’s resignation was not the result of any disagreement with ARCA on any matter relating to ARCA’s operations, policies or practices. In connection with Dr. Woosley’s and Mr. Mitchell’s resignations, the Board reduced the size of the Board from eight (8) to six (6) directors.공시 • Dec 20ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024, at 09:00 US Mountain Standard Time. Location: Denver Marriott Westminster 7000 Church Ranch Blvd, Westminster, Colorado 80021 Colorado United States Agenda: To elect the Board of Directors’ nominees, Dr. Michael R. Bristow and Mr. Robert E. Conway, to the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders; to ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the company for its fiscal year ending December 31, 2023; to approve, on an advisory basis, the compensation of the company’s named executive officers, as disclosed in this proxy statement; and to consider any other business that is properly brought before the meeting.공시 • Feb 15ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General CounselARCA biopharma, Inc. and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023. Mr. Ozeroff's departure is not the result of any disagreement with ARCA on any matter relating to its operations, policies or practices, or regarding the general direction of the company.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director Jacob Ma-Weaver was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Sep 24Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • May 03ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation PlayActivist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. The company's cash position (minus liabilities) stands at $3.19/share offering a potential 45% upside if things play out according to the activist's demands.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Anders Hove was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Nov 27Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Recent Insider Transactions • Nov 25Senior VP recently bought US$113k worth of stockOn the 22nd of November, Christopher Ozeroff bought around 50k shares on-market at roughly US$2.26 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$219k more in shares than they have sold in the last 12 months.분석 기사 • Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Executive Departure • May 15Chief Accounting Officer & VP of Finance has left the companyOn the 10th of May, Brian Selby's tenure as Chief Accounting Officer & VP of Finance ended after 6.4 years in the role. We don't have any record of a personal shareholding under Brian's name. Brian is the only executive to leave the company over the last 12 months.분석 기사 • Mar 30Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Mar 05New 90-day low: US$3.98The company is down 5.0% from its price of US$4.19 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Feb 09New 90-day high: US$4.93The company is up 27% from its price of US$3.87 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: US$4.55The company is up 6.0% from its price of US$4.29 on 15 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.분석 기사 • Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 10New 90-day low: US$3.81The company is down 44% from its price of US$6.79 on 11 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.Is New 90 Day High Low • Oct 24New 90-day low: US$4.03The company is down 42% from its price of US$6.91 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: US$4.18The company is down 39% from its price of US$6.85 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.매출 및 비용 세부 내역ARCA biopharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:ABIO 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 240-78131 Mar 240-67131 Dec 230-56130 Sep 230-56130 Jun 230-66131 Mar 230-86231 Dec 220-106430 Sep 220-146930 Jun 220-1761131 Mar 220-1851331 Dec 210-1961430 Sep 210-1961330 Jun 210-1651131 Mar 210-135831 Dec 200-105530 Sep 200-64230 Jun 200-54131 Mar 200-54231 Dec 190-54230 Sep 190-64230 Jun 190-64231 Mar 190-74331 Dec 180-84430 Sep 180-114630 Jun 180-135931 Mar 180-1751331 Dec 170-1851430 Sep 170-1941430 Jun 170-1941531 Mar 170-1741331 Dec 160-1641230 Sep 160-1541130 Jun 160-144931 Mar 160-124831 Dec 150-114730 Sep 150-114730 Jun 150-104631 Mar 150-104631 Dec 140-104630 Sep 140-104630 Jun 140-94531 Mar 140-104431 Dec 130-943양질의 수익: ABIO 은(는) 현재 수익성이 없습니다.이익 마진 증가: ABIO는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ABIO은 수익성이 없으며 지난 5년 동안 손실이 연평균 2.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ABIO의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ABIO은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ABIO는 현재 수익성이 없으므로 자본 수익률이 음수(-22.1%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/29 05:27종가2024/08/29 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ARCA biopharma, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Edward WooAscendiant Capital Markets LLC
분석 기사 • Apr 04Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Apr 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 8.4% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$47.1m market cap).
공시 • Feb 09Arca Biopharma, Inc. Announces Executive ChangesARCA biopharma, Inc. announced on February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors of the company, effective immediately. Upon the effectiveness of their resignations, Dr. Woosley and Mr. Mitchell each ceased to serve on any Board committees, including as Chairperson of the Nominating & Corporate Governance Committee and as member of the Compensation Committee, and as member of the Audit Committee and Nominating & Corporate Governance Committee, respectively. Each of Dr. Woosley’s and Mr. Mitchell’s resignation was not the result of any disagreement with ARCA on any matter relating to ARCA’s operations, policies or practices. In connection with Dr. Woosley’s and Mr. Mitchell’s resignations, the Board reduced the size of the Board from eight (8) to six (6) directors.
공시 • Dec 20ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024, at 09:00 US Mountain Standard Time. Location: Denver Marriott Westminster 7000 Church Ranch Blvd, Westminster, Colorado 80021 Colorado United States Agenda: To elect the Board of Directors’ nominees, Dr. Michael R. Bristow and Mr. Robert E. Conway, to the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders; to ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm of the company for its fiscal year ending December 31, 2023; to approve, on an advisory basis, the compensation of the company’s named executive officers, as disclosed in this proxy statement; and to consider any other business that is properly brought before the meeting.
공시 • Feb 15ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General CounselARCA biopharma, Inc. and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023. Mr. Ozeroff's departure is not the result of any disagreement with ARCA on any matter relating to its operations, policies or practices, or regarding the general direction of the company.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director Jacob Ma-Weaver was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Sep 24Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • May 03ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation PlayActivist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. The company's cash position (minus liabilities) stands at $3.19/share offering a potential 45% upside if things play out according to the activist's demands.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Anders Hove was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Nov 27Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Recent Insider Transactions • Nov 25Senior VP recently bought US$113k worth of stockOn the 22nd of November, Christopher Ozeroff bought around 50k shares on-market at roughly US$2.26 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$219k more in shares than they have sold in the last 12 months.
분석 기사 • Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Executive Departure • May 15Chief Accounting Officer & VP of Finance has left the companyOn the 10th of May, Brian Selby's tenure as Chief Accounting Officer & VP of Finance ended after 6.4 years in the role. We don't have any record of a personal shareholding under Brian's name. Brian is the only executive to leave the company over the last 12 months.
분석 기사 • Mar 30Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Mar 05New 90-day low: US$3.98The company is down 5.0% from its price of US$4.19 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Feb 09New 90-day high: US$4.93The company is up 27% from its price of US$3.87 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: US$4.55The company is up 6.0% from its price of US$4.29 on 15 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.
분석 기사 • Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 10New 90-day low: US$3.81The company is down 44% from its price of US$6.79 on 11 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Oct 24New 90-day low: US$4.03The company is down 42% from its price of US$6.91 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: US$4.18The company is down 39% from its price of US$6.85 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.